Navigation Links
Dasatinib Shows High Early Response Rate as First Treatment for,Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report

CHICAGO, June 2, 2007 - An established second-line drug for chronic myelogenous leukemia has high response rates when given to newly diagnosed patients as their first therapy for the disease, according to early results from a Phase II clinical trial at The University of Texas M. D. Anderson Cancer Center.

"Patients taking dasatinib achieve complete cytogenetic response - absence of the mutated protein that drives this disease - more rapidly than we've observed historically using the current front-line therapy. Side effects are very manageable," says Ehab L. Atallah, M.D., lead author of the study and a fellow in M. D. Anderson's Department of Leukemia. Atallah presented study results at the annual meeting of the American Society of Clinical Oncology in Chicago Saturday June 2nd, 2007. The clinical trial remains in progress with 35 patients enrolled.

Dasatinib, known commercially as Sprycel and produced by Bristol-Myers Squibb, was approved by the U.S. Food and Drug Administration a year ago for use by patients whose disease is unresponsive to or becomes resistant to the front-line therapy imatinib. Both drugs bind to and block a genetically flawed protein known as BCR-ABL, which causes the disease. Atallah explains that dasatinib binds to both forms BCR-ABL while imatinib blocks only one.

"Our hypothesis is that treating with dasatinib first will produce an earlier response, which may translate to a better overall survival," Atallah says. "We haven't proved that here, but these early results are encouraging."

Atallah and colleagues evaluated 35 patients who enrolled in the clinical trial between November 2005 and December 2006. Patients receive either 100 mg of dasatinib once daily or 50 mg twice daily.

Thirty four patients had been on the clinical trial for at least three months when Atallah and lead researcher Jorge Cortes, M.D., professor in the Department of Leukemia, eva
'"/>




Page: 1 2 3

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:12/22/2014)... Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a ... blood purification technology to help fight deadly inflammation ... countries worldwide, today announced the appointment of Dr. ... as its Senior Vice President of Clinical Development, ... Di Russo is an accomplished pediatric ...
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ( ... offices in Aliso Viejo , California.  ... to the tremendous growth and worldwide expansion, a new ... patented SnoreRx, the anti snore cure have exceeded our ... "We are now in 23 countries and will ...
(Date:12/22/2014)... 22, 2014   TRU-D SmartUVC LLC, producers ... robot, announced today that the General Services Administration has ... 2019.   This newly formed agreement will ... of government purchasers, including Department of Veteran Affairs and ... Security contacts purchasing solutions for the Ebola effort in ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... Like many other diagnostic regimes that were previously ... entering the clinical mainstream. Smaller, simpler analyzer systems ... large physicians group labs, while some genetic test ... care locations such as clinics and physician offices., ...
... to plan or evaluate anticoagulant therapy, to ... elevated factor VIII levels, dysfibrinogenemia, factor XII ... to assess acquired conditions, such as pregnancy, ... Prothrombin levels are also monitored along with ...
Cached Medicine Technology:Genetic Analysis Systems Enter the Clinical Mainstream 2Genetic Analysis Systems Enter the Clinical Mainstream 3Prothrombin Time Comes in Small (CLIA-Waived) Packages 2Prothrombin Time Comes in Small (CLIA-Waived) Packages 3
(Date:12/25/2014)... 2014 The report “TS-1 (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... an anti-cancer drug which is typically used for treating ... used for treating gastric cancer and pancreatic cancer. TS-1 ... drug was first approved in 1999 in Japan for ...
(Date:12/25/2014)... 26, 2014 Recently, iFitDress.com, the popular online ... has announced its new selection of black one-shoulder cocktail ... sale now; they are available at discounted prices, up to ... promotion will last for three weeks only. You know, we ... who are interested in our new items can visit our ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... FL (PRWEB) December 25, 2014 When head ... find themselves in a frenzy to get rid of it ... But families in Coral Gables now have the solution right ... second salon clinic location, Lice Troopers provides full spectrum head ... the Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut ...
(Date:12/25/2014)... THURSDAY, Dec. 25, 2014 (HealthDay News) -- The risk ... the holidays, so you need to be extra cautious, ... Day, we see a significant increase in patients coming ... at the Suffolk County Volunteer Firefighters Burn Center of ... celebrations should be full of joy, but if not ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2
... being male did have a correlation , , FRIDAY, March ... extent of head flattening in infants, U.S. researchers say. ... asymmetrical head shape, known as deformational plagiocephaly (DP), in ... Since the early 1990s, parents have been encouraged to ...
... stents were safe and superior to bare metal stents ... patients enrolled in a nationwide registry of cardiovascular disease, ... , The findings were presented today at the i2Summit ... Session. They also appear online in the Journal ...
... Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") ... ended December 31, 2008. For the three months ended December ... from revenues of $389,000 in the prior year period, and ... compared with net income of $38,000 ($0.01 per share) for ...
... March 27 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) ... company announced the clinical trial protocol for their MMR ... approved by the end of the second quarter 2009. ... live attenuated viruses administered via injection for immunization against ...
... and Social Responsibility Targets to be met by ... Gamble Company (NYSE: PG ) today ... goals. The updates reflect the company,s continued ... of P&G,s products and operations and bettering lives ...
... of the Simulated Impaired Driving Experience(R), (SIDNE(R)), will be ... the Lifesavers conference at the Gaylord Opryland Resort and ... 31. The Lifesavers Conference is a national traffic safety ... our nation,s roadways. "We are excited to demonstrate our ...
Cached Medicine News:Health News:Baby's Sleep Position May Not Affect Severity of Head Flattening 2Health News:Drug-eluting stents found safe, superior to bare metal stents 2Health News:Human Pheromone Sciences Announces Fourth Quarter and Full Year Results 2Health News:Human Pheromone Sciences Announces Fourth Quarter and Full Year Results 3Health News:Human Pheromone Sciences Announces Fourth Quarter and Full Year Results 4Health News:Human Pheromone Sciences Announces Fourth Quarter and Full Year Results 5Health News:Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009 2Health News:Procter & Gamble Deepens Corporate Commitment to Sustainability 2Health News:Procter & Gamble Deepens Corporate Commitment to Sustainability 3Health News:Innocorp, ltd. to Attend Lifesavers Conference 2
The Thermal pads were designed to simulate water immersion, the most effective method of transferring energy non-invasively....
This blanket is ideal for warming the large child or small adult during upper body surgery....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
Medicine Products: